Introduction
Papaverine is an alkaloid of the benzylisoquinoline group and has been widely used as a smooth muscle relaxant for more than a century. It decreases cerebrovascular resistance and papaverine hydrochloride has been much used in the U.S.A. in recent years in patients with cerebral arterial disease and peripheral arterial disease (Jayne, Scheinberg and Belle, 1952; Whittier, 1964; Stern, 1970) . Side effects following oral administration were considered insignificant and largely limited to nausea, vomiting or throbbing headache. Hepatotoxic sequelae to papaverine administration were first reported in 4 elderly patients (R0nnov-Jessen and Tjerlund, 1969 ). An increase in serum alkaline phosphatase levels may occur in up to 43 % of older people on daily papaverine (Dreimen, 1973) , although this has been refuted (Gillis, 1973 function tests. Of the remainder, the drug was discontinued in one patient after 2 weeks owing to nausea, vomiting and abdominal pain, but, unfortunately, the liver function tests were not documented. After 2-12 weeks on papaverine, 3 patients had mild elevations of serum alkaline phosphatase levels ranging from 48-57 i.u./l (normal, 10-40) and in one patient the y-glutamyl transpeptidase (y-GT) rose to 69 i.u./l (normal, < 45).
The remaining 3 patients had more marked abnormalities:
Patient no. 1 After 3 weeks on Pavigrad he complained of nausea and developed jaundice the following day.
The bilirubin rose to 74 ,umol/l (normal, < 17), the aspartate aminotransferase (AST) to 130 i.u. (normal, 10-40) , alkaline phosphatase to 130 i.u./l, and y-GT to 343 i.u./l. The drug was discontinued and the jaundice subsided and liver function tests reverted to normal.
Patient no. 2
A 72-year-old female who had a slight pre-trial elevation of the alkaline phosphatase at 47 i.u./l, after taking Pavigrad for 5 weeks, reported that her urine was dark. The liver function tests were as follows: bilirubin, 38 ,umol/l; AST, 69 i.u./l; alkaline phosphatase, 190 i.u./l; and y-GT, 1080 i.u./l. The drug was discontinued. Although the liver function tests started to improve, she developed a myocardial infarction and severe congestive heart failure in week 9. A liver biopsy showed the liver architecture to be normal and there was no evidence of cholestasis or cell necrosis (Fig. 1) AST 92 i.u./l; alkaline phosphatase 59 i.u./l; and y-GT, 312 i.u./I. Papaverine was discontinued and the tests returned to normal within 4 weeks.
Discussions and conclusions
The hepatotoxicity of papaverine was first noted in 4 patients by R0nnov-Jessen and Tjerlund (1969) . In a later study, 13 out of 30 elderly patients were found to have developed an elevated serum alkaline phosphatase after the oral administration of sustained release papaverine (Driemen, 1973) ; but in another report no clinical or biochemical evidence of hepatotoxicity could be ascertained in 29 elderly patients receiving 600 mg of Pavigrad daily for 19 weeks (Gillis, 1973) . R0nnov-Jessen and Tjerlund (1969) and Kiaer, Olsen and R0nnov-Jessen (1974) reported the liver histology characteristically to show diffuse proliferation of the Kupffer cells and infiltration of the portal spaces with eosinophilic granulocytes, although the latter finding was absent in one of their patients. Kiaer et al. (1974) gave repeated courses of papaverine with production of recurrent evidence of hepatoxicity to some of their patients and included in their study 2 patients originally reported by R0nnov-Jessen and Tjerlund. They found that all patients exposed anew produced prompt reactions. They consider that this finding and the presence of eosinophilic infiltration of the portal spaces indicated that the hepatotoxic action of papaverine includes an allergic factor. Zimmerman (1969) suggested that papaverine-induced liver injury might be due to a combination of allergy to the drugs and to a metabolic aberration of the host permitting the accumulation of hepatotoxic metabolites.
Changes in liver function tests occurred in the authors' patients after a latent period of 2-12 weeks which is comparable to the 3-6 weeks in the series of Kiaer et al. (1974) . All authors have noted a rapid return of liver function tests to normal on discontinuing the drug. This finding was also noted in the present patients with the exception of patient no. 2 who developed severe congestive heart failure following a myocardial infarction at week 9. Six of the 14 subjects in the present study had biochemical evidence of altered hepatic function, the most consistent changes being an elevation in the serum alkaline phosphatase or y-GT, typical of a portal infiltrate or granulomata, although the elevated AST levels in some patients suggest hepatocellular damage. The absence of eosinophils in the present biopsy compared to other published cases may be due to the fact that the specimen was taken after discontinuation of the drug.
Mild to moderately severe changes in liver function tests in 50% of a carefully supervised group of elderly patients receiving papaverine suggests that this drug is inappropriate for the elderly. A trial of papaverine in intellectualy impaired patients with cerebro-vascular disease was accordingly abandoned.
